Gordon Gochenauer

Senior Director

Dr. Paul Harney

Chief Commercial Officer

Michael White

Senior Vice President

Dr. Milagros Rojas

Associate Consultant

Advances in the treatment of MM have delivered promising long-term outcomes, but these outcomes come with the expectation of multiple regimens over many lines of therapy. Ensuring a patient receives the most appropriate combination regimen according to their individual characteristics, including their comorbidities and risk of recurrence, is instrumental in initiating a sequence of suitable treatments, and pharmaceutical companies, healthcare providers and patient support groups can play a key role in recognizing MM as a chronic disease.

In this white paper, we will explore the shift in perceptions of MM to a chronic disease through a review of:

  • The role of combination therapies in extending survival
  • The evolving challenges for physicians and healthcare providers
  • Critical differences between clinical trials and real-world evidence
  • What now marks MM as a chronic disease
  • Future perspectives on MM

While a cure will undoubtedly continue to be the ultimate goal from a research and treatment standpoint, a more holistic perspective could change our understanding of MM from an incurable cancer to a chronic disease.

Download your free copy of the white paper by completing the form.